Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | GNA15 | P30679 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506293 | 0.90 | HDAC1 (0.58) | FFAR1HDAC1HDAC8HDAC6TP53 | |
| SCHEMBL6507649 | 0.78 | HDAC1 (0.46) | TDP1HDAC1HDAC8HDAC6TP53 | |
| SCHEMBL6513479 | 0.77 | ALDH1A1 (0.54) | FFAR1TDP1HDAC1HDAC8HDAC6 | |
| SCHEMBL6510152 | 0.77 | HDAC2 (0.52) | HDAC1HDAC8HDAC6TP53MAPT | |
| SCHEMBL6512229 | 0.74 | TP53 (0.40) | HDAC1HDAC8HDAC6TP53MAPT | |
| SCHEMBL4927605 | 0.74 | HDAC3 (0.59) | TDP1HDAC1HDAC8HDAC6TP53 | |
| SCHEMBL6514847 | 0.74 | TP53 (0.40) | HDAC1HDAC8HDAC6TP53MAPT | |
| SCHEMBL6514506 | 0.73 | INSR (0.57) | HDAC1HDAC8HDAC6MAPTSMN1; SMN2 | |
| SCHEMBL25366655 | 0.73 | HPGD (0.53) | TP53SMN1; SMN2 | |
| SCHEMBL6512208 | 0.71 | MAOA (0.49) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | FFAR1 4065/4885FFAR4 4179/4885GNA15 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.